A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2018
Price : $35 *
At a glance
- Drugs Donepezil/solifenacin (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Chase Pharmaceuticals
- 27 Jul 2016 According to a Chase Pharmaceuticals media release, the data was presented at the 2016 Alzheimers Association Conference (AAIC).
- 27 Jul 2016 Results published in the Chase Pharmaceuticals media release.
- 25 Jul 2016 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History